These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Tagawa Y; Nishimura R; Ishiko O; Kanai Y; Yaegashi N; Aburatani H; Shiozawa T; Konishi I Sci Rep; 2011; 1():180. PubMed ID: 22355695 [TBL] [Abstract][Full Text] [Related]
4. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma. Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613 [TBL] [Abstract][Full Text] [Related]
5. Reduced expression of calponin h1 in leiomyosarcoma of the uterus. Horiuchi A; Nikaido T; Ito K; Zhai Y; Orii A; Taniguchi S; Toki T; Fujii S Lab Invest; 1998 Jul; 78(7):839-46. PubMed ID: 9690561 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. Matsumura N; Mandai M; Miyanishi M; Fukuhara K; Baba T; Higuchi T; Kariya M; Takakura K; Fujii S Clin Cancer Res; 2006 Mar; 12(5):1402-11. PubMed ID: 16533762 [TBL] [Abstract][Full Text] [Related]
7. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912 [TBL] [Abstract][Full Text] [Related]
8. Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma. Horiuchi A; Nikaido T; Taniguchi S; Fujii S J Natl Cancer Inst; 1999 May; 91(9):790-6. PubMed ID: 10328110 [TBL] [Abstract][Full Text] [Related]
9. Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. Weissenbacher T; Kuhn C; Mayr D; Pavlik R; Friese K; Scholz C; Jeschke U; Ditsch N; Dian D Anticancer Res; 2011 Feb; 31(2):451-7. PubMed ID: 21378323 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas. Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250 [TBL] [Abstract][Full Text] [Related]
11. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors. Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677 [TBL] [Abstract][Full Text] [Related]
12. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. Petrović D; Babić D; Forko JI; Martinac I Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637 [TBL] [Abstract][Full Text] [Related]
13. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study. Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Leiomyomatoid Angiomatous Neuroendocrine Tumour (LANT)-like Tumour in the Myometrium with Histopathological Examination. Hayashi T; Ichimura T; Kasai M; Sano K; Zharhary D; Shiozawa T; Yaegashi N; Konishi I Anticancer Res; 2017 Apr; 37(4):1765-1772. PubMed ID: 28373439 [TBL] [Abstract][Full Text] [Related]
15. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786 [TBL] [Abstract][Full Text] [Related]
16. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study. Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146 [TBL] [Abstract][Full Text] [Related]
17. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581 [TBL] [Abstract][Full Text] [Related]
18. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039 [TBL] [Abstract][Full Text] [Related]
19. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Amada S; Nakano H; Tsuneyoshi M Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525 [TBL] [Abstract][Full Text] [Related]
20. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Atkins KA; Arronte N; Darus CJ; Rice LW Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]